A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma
Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Ajit Nair(Rhizen Pharmaceuticals (Switzerland)), Kasi V. Routhu(Rhizen Pharmaceuticals (Switzerland)), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Tatyana Feldman(Hackensack University Medical Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Ryan A. Wilcox(University of Michigan), Auris Huen(University of Pennsylvania), Timothy M. Kuzel(Rush University), Prajak J. Barde(Rhizen Pharmaceuticals (Switzerland)), Weiyun Z. Ai(City College of San Francisco), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Ann Mohrbacher(University of Southern California), Mary Jo Lechowicz(Emory University), Nishitha Reddy(Vanderbilt University), Craig Okada(Oregon Health & Science University), Don A. Stevens(Norton Healthcare), Bradley M. Haverkos(University of Colorado Denver)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k